Influence of a genomic classifier on post-operative treatment decisions in high-risk prostate cancer patients: Results from the PRO-ACT study

Current Medical Research and Opinion

Volumn 30, Issue 8, 2014, Pages 1547-1556

  Michalopoulos, Steven N ^a   Kella, Naveen ^b   Payne, Ryan ^c   Yohannes, Paulos ^d   Singh, Amar ^e,f   Hettinger, Christian ^g   Yousefi, Kasra ^h   Hornberger, John ^a,i  

^a Cedar Associates   (United States)

^b Urology and Prostate Institute   (United States)

^c Salina Urology Associates   (United States)

^d Urology Health Center   (United States)

^e UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^f Erlanger Medical Center   (United States)

^g Kansas City Urology Care   (United States)

^h GenomeDx Biosciences Inc   (Canada)

ⁱ STANFORD UNIVERSITY   (United States)

Author keywords

Decision impact; Metastasis; Patient management; Prognosis; Prostate cancer

Indexed keywords

ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CLINICAL DECISION MAKING; DECISION CONFLICT SCALE; GENOMIC CLASSIFIER TEST; GENOMICS; HIGH RISK PATIENT; HUMAN; METASTASIS; MULTICENTER STUDY (TOPIC); POSTOPERATIVE CARE; PROSTATE CANCER; PROSTATECTOMY; RATING SCALE; UROLOGIST; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; CLINICAL TRIAL; DECISION SUPPORT SYSTEM; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; WATCHFUL WAITING;

AGED; CHEMOTHERAPY, ADJUVANT; DECISION SUPPORT TECHNIQUES; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOMICS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; POSTOPERATIVE CARE; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; WATCHFUL WAITING;

EID: 84904887342     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.919908     Document Type: Article

References (30)

1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. Cancer J Clin 2014;64:9-29
2. Bastian PJ, Boorjian SA, Bossi A, et al. High-risk prostate cancer: from definition to contemporary management. Eur Urol 2012;61:1096-106
3. Swanson GP, Basler JW. Prognostic factors for failure after prostatectomy. J Cancer 2010;2:1-19.
4. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005;366:572-8
5. Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012;380:2018-27
6. Thompson Jr IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006;296:2329-35
7. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol Off J Am Soc Clin Oncol 2009;27:2924-30
8. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009;181:956-62
9. Thompson IM, Valicenti RK, Albertsen P, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol 2013;190:441-9
10. Cooperberg MR, Simko JP, Cowan JE, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol Off J Am Soc Clin Oncol 2013;31:1428-34
11. Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011;12:245-55
12. Erho N, Crisan A, Vergara IA, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PloS One 2013;8:e66855
13. Karnes RJ, Bergstralh EJ, Davicioni E, et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol 2013;190:2047-53
14. Ross AE, Feng FY, Ghadessi M, et al. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer Prostatic Dis 2014;17:64-9
15. Badani K, Thompson D, Brown G, et al. Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery. BJU Int 2014; Epub 2014/04/30
16. Hornberger J. Assigning value to medical algorithms: implications for personalized medicine. Pers Med 2013;10:577-88
17. Hornberger J, Doberne J, Chien R. Laboratory-developed test-SynFRAME: an approach for assessing laboratory-developed tests synthesized from prior appraisal frameworks. Genet Test Mol Biomarkers 2012;16:605-14
18. Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med Off J Am Coll Med Genet 2009;11:3-14
19. Dolan JG. A method for evaluating health care providers' decision making: the Provider Decision Process Assessment Instrument. Med Decis Making Int J Soc Med Decis Making 1999;19:38-41
20. Team RDC. R: a language and environment for statistical computing. Vietta, Austria: R Foundation for Statistical Computing, 2008. Available at: http://www.r-project.org/. Accessed March 18, 2014
21. Punnen S, Freedland SJ, Presti JC, Jr., et al. Multi-institutional validation of the CAPRA-S Score to predict disease recurrence and mortality after radical prostatectomy. Eur Urol 2013;65:1171-77
22. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 2011;117:5039-46
23. Palmetto GBA Medicare. Molecular Diagnostic Program (MolDxSM): Coverage, Coding, and Pricing Standards and Requirements. Lawrence: Palmetto GBA, 2014
24. Hornberger J, Alvarado MD, Rebecca C, et al. Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review. J Natl Cancer Inst 2012;104:1068-79
25. Badani K, Thompson DJ, Buerki C, et al. Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget 2013;4:600-9
26. Crawford ED, Scholz MC, Kar AJ, et al. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Curr Med Res Opin 2014; Epub 2014/03/01
27. Shore N, Concepcion R, Saltzstein D, et al. Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. Curr Med Res Opin 2014;30:547-53
28. Robertson DJ, Dominitz JA. Stool DNA and colorectal-cancer screening. N Engl J Med 2014;370:1350-1
29. Murphy SB, Patlak M, National Cancer Policy Forum (U.S.), Institute of Medicine (U.S.). Board on Health Care Services. A foundation for evidencedriven practice: a rapid learning system for cancer care: workshop summary. Washington, D.C.: National Academies Press, 2010:109
30. Hayes DF, Allen J, Compton C, et al. Breaking a vicious cycle. Sci Transl Med 2013;5:196cm6